Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
PARI Pharma’s eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed’s ARIKAYCE® (amikacin liposome inhalation suspension).
Monitoring nebuliser usage & lung function in clinical trials.
Monitoring adherence to treatment regimen of inhaled medication use in a clinical trial with an investigational eFlow nebulizer (eTrack).
MagnairTM an eFlow® Closed System Nebulizer together with Sunovion’s LonhalaTM is the first eFlow Technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)
In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution.
